# TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

> **NCT05729711** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 416 (actual)

## Conditions studied

- Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05729711
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2029-11-16
- **Final completion:** 2029-11-16
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05729711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05729711, "TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05729711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*